State Street Increases Stake in Avadel Pharmaceuticals by 2.35%

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Dec 30 2025

0mins

AVDL+0.42%

Should l Buy AVDL?

Source: Globenewswire

Stake Increase: State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc to 2.35% as of December 29, 2025, indicating confidence in the company's growth potential and future prospects.
Transaction Details: The transaction involved 2,290,449 ordinary shares, reflecting State Street's investment strategy aimed at enhancing its market influence in the biopharmaceutical sector through increased ownership.
Market Reaction: This stake increase may positively impact Avadel's stock price, reflecting institutional investors' optimistic expectations for its future performance, thereby attracting further investor interest.
Strategic Implications: State Street's increased stake not only strengthens its control over Avadel but may also provide greater voting power, allowing for a more significant role in future corporate decisions.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy AVDL?" and start using high-conviction signals backed by rigorous historical data.

AVDL

$21.69+Infinity%1D

Analyst Views on AVDL

Wall Street analysts forecast AVDL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is 20.29 USD with a low forecast of 18.50 USD and a high forecast of 22.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Analyst Rating

0 Buy

10 Hold

0 Sell

Hold

Current: 21.600

Low

18.50

Averages

20.29

High

22.50

Current: 21.600

Low

18.50

Averages

20.29

High

22.50

Wells Fargo

Equal Weight

maintain

$20

2025-11-20

Reason

Wells Fargo

Price Target

$20

AI Analysis

2025-11-20

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $20 and keeps an Equal Weight rating on the shares. The firm says updated Alkermes' (ALKS) offer looks better to Wells, with a similar upfront but better CVR terms that it thinks are likely to pay out.

Truist

initiated

$50

2025-11-11

Reason

Truist

Price Target

$50

2025-11-11

initiated

Reason

Truist initiated coverage of Alkermes (ALKS) with a Buy rating and $50 price target. The firm values the base business and cash at about $29 per share, which it sees "setting a high floor" heading into Phase 2 Vibrance-2 data in narcolepsy type 2. Narcolepsy type 1 alone is worth $8 per share in the firm's sum-of-the-parts valuation, while NT2 and idiopathic hypersomnia contribute $8 per share and $5 per share, respectively, the analyst tells investors. Alkermes "doubling down" in sleep space with the acquisition of Avadel (AVDL) is a strategic move that gives it a first-mover advantage over Takeda (TAK), the analyst added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AVDL

Unlock Now

About AVDL

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

State Street Increases Stake in Avadel Pharmaceuticals by 2.39%

Jan 19 2026Globenewswire

Stake Increase: State Street Global Advisors and affiliates increased their stake in Avadel Pharmaceuticals plc on January 16, 2026, holding 2,326,632 shares, which represents 2.39% of total shares, indicating confidence and investment intent in the company.
Transaction Details: In this transaction, State Street purchased a total of 29,196 shares at a price of $21.48 each, reflecting optimism about Avadel's future growth potential, which may influence the overall market perception of the stock.
Market Reaction: This stake increase could attract market attention towards Avadel Pharmaceuticals, especially if the stock price remains stable, prompting investors to reassess the company's value and prospects.
Disclosure Compliance: In accordance with the Irish Takeover Panel regulations, State Street's trading information was disclosed on January 19, 2026, ensuring transparency and compliance, which further enhances market trust in its regulatory adherence.

State Street Increases Stake in Avadel Pharmaceuticals by 2.36%

Jan 16 2026Globenewswire

Stake Increase: State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc on January 15, 2026, holding 2,298,069 shares, which represents 2.36% of total shares, indicating confidence and a long-term investment strategy in the company.
Transaction Price: The purchase price per share was $621.48, reflecting market recognition of Avadel, which may influence its stock price trajectory and increase investor interest in the company.
Market Impact: State Street's stake increase could enhance Avadel's visibility among investors, attracting more institutional interest and potentially driving up its stock price, thereby boosting market confidence.
Future Outlook: With State Street's increased stake, Avadel Pharmaceuticals may gain more market support and resources in the future, further driving its business development and market expansion.

State Street Increases Stake in Avadel Pharmaceuticals, Holding Reaches 2.36%

Jan 15 2026Globenewswire

Increased Stake: State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc on January 14, 2026, holding 2,298,063 shares, which represents 2.36% of total shares, indicating ongoing confidence in the company.
Transaction Details: In this transaction, State Street purchased 6,500 shares at $21.50 each while simultaneously selling the same number of shares, reflecting an active trading strategy in the market.
Market Impact Analysis: This increase in stake may positively influence Avadel's stock price, enhancing market confidence in its future growth potential, particularly in the context of its product line expansion and strategic adjustments.
Transparency and Compliance: The disclosure of State Street's transactions complies with the regulations set by the Irish Takeover Panel, further enhancing market trust in its compliance practices.

Avadel Pharmaceuticals Shareholders Approve Alkermes Buyout

Jan 12 2026Yahoo Finance

Acquisition Approval: Shareholders of Avadel Pharmaceuticals have approved the buyout proposal by Alkermes, marking a significant step in the company's strategic restructuring, which is expected to enhance Alkermes' market position in the biopharmaceutical sector.
Shareholder Support: The vote reflects broad shareholder support for the acquisition, indicating confidence in the future integration benefits and synergies, which may enhance both companies' capabilities in research and marketing.
Market Reaction: Following the acquisition announcement, the market showed a positive response towards the stocks of Avadel and Alkermes, indicating optimistic expectations from investors, which could drive stock prices higher.
Strategic Integration: This acquisition will enable Alkermes to expand its product portfolio and leverage Avadel's technology platform, further solidifying its competitive advantage in therapeutic areas and laying the groundwork for future growth.

State Street Increases Stake in Avadel Pharmaceuticals by 2.36%

Jan 09 2026Globenewswire

Stake Increase: On January 8, 2026, State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc to 2,299,746 shares, representing 2.36% of total shares, indicating confidence in the company's prospects.
Transaction Price: The purchase price for this stake was $21.48 per share, reflecting market recognition of Avadel's future growth potential, which may influence investor sentiment towards the stock.
Market Impact: State Street's stake increase could enhance Avadel's market image, attracting more investor attention and potentially driving the stock price up in the short term, thereby strengthening its competitive position in the biopharmaceutical sector.
Investment Strategy: This transaction indicates State Street's long-term investment strategy in Avadel, suggesting a possibility of further increasing their stake to capitalize on the company's potential growth opportunities in the pharmaceutical industry.